Resolian
The challenges of large molecule bioanalysis by LC–MS: an interview with Rob Wheller
Interview with Rachel Green (LGC) on her current work with biomarkers
Panel discussion: the value of HRMS vs. QQQ for DMPK studies
Panel discussion: strategies and challenges of immunogenicity
Lack of standardization in immunogenicity – a CRO perspective
Resolian Opens Expanded State-of-the-Art Analytical Laboratory in Fordham
Alliance Pharma and Drug Development Solutions are now Resolian
LGC extend regulated bioanalytical LC–MS service
LGC extend regulated bioanalytical LC–MS service
LGC COVID-19 antibody assay suitable for serum and dried blood sampling
Resolian (formerly Alliance Pharma Inc and Drug Development Solutions, Ltd) is a leading global research laboratory that provides specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science.
Our team of more than 500 experts across the US, UK, and Australia supports pharma and biotech companies throughout their drug development continuum. Resolian’s specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, and drug metabolism.
Our dedicated laboratories, equipped with state-of-the-art technology are ready to meet the needs of preclinical and clinical programs at any scale. Resolian delivers quality results and ensures the highest standard of regulatory compliance in all phases of research.
Our team of experts works closely with clients to understand their needs and develop customized solutions that clarify their best path forward. Resolian’s extensive expertise, advanced technology, and commitment to quality make us a trusted partner for companies at any size or stage of drug development.
Realize your product’s potential with Resolian.
Website: www.resolian.com